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Mammalian -globin loci contain multiple -like genes that are
expressed at different times during development. The murine
-globin locus contains two genes expressed during the embryo
stage, Ey and h1, and two genes expressed at both the fetal and
postnatal stages, -major and -minor. Studies of transgenic hu-
man -like globin loci in mice have suggested that expression of
one gene at the locus will suppress expression of other genes at the
locus. To test this hypothesis we produced mouse lines with
deletions of either the Ey or h1 promoter in the endogenous
murine -globin locus. Promoter deletion eliminated expression of
the mutant gene but did not affect expression of the remaining
embryonic gene or the fetaladult -globin genes on the mutant
allele. These results demonstrate a lack of competitive effects
between individual mouse embryonic -globin gene promoters
and other genes in the locus. The implication of these findings for
models of -globin gene expression are discussed.
In mammals there are multiple -globin genes, expressed atdifferent stages of development, that encode -like globins
which combine with -like globins to form hemoglobin. The
developmentally regulated pattern of -globin gene expression
is known as -globin switching (reviewed in ref. 1). During
embryonic development, primitive erythrocytes produced in the
yolk sac blood islands express -globin in humans and predom-
inantly Ey and h1 globins in mice. Later during development,
the embryonic genes are silenced, and definitive erythrocytes,
produced in the fetal liver, express G and A -like globins in
humans or -major and -minor in a 6040 ratio in mice. Close
to the time of birth, the site of erythropoiesis switches to the
bone marrow, and a second globin switch occurs in humans, with
both  genes being silenced and the  gene becoming the
predominant -like globin expressed throughout postnatal hu-
man life. In mice the definitive erythrocytes produced in the
bone marrow express the -major and -minor genes as during
fetal liver erythropoiesis but with a changed ratio of 8020. In
both human and mouse loci, all genes are expressed from the
same strand and are arranged in their order of expression during
development (Fig. 1A). -Globin gene switching is of interest
both as a model for complex stage- and tissue-specific gene
expression and as a potential target for gene therapy, because
activation of the silenced human -globin genes postnatally
could greatly ameliorate the common genetic disorders of sickle
cell disease and -thalassemia.
Regulation of the -globin locus has been studied extensively
in transgenic mice carrying portions of the human locus and in
mice in which the endogenous mouse locus is modified by
homologous recombination. Additional insights into globin gene
regulation have been derived from studies of the many human
-globin locus mutations found in human populations that
coexist with Plasmodium falciparum, the red-cell parasite that
causes malaria (reviewed in ref. 2). However, understanding of
the mechanisms of globin gene switching remains incomplete.
One consensus is that -globin gene activation involves both
gene-proximal and -distal regulatory elements (reviewed in ref.
1). The most prominent distal regulatory element is the locus
control region (LCR). The murine -globin LCR spans 5–22 kb
5 of the Ey gene and has five tissue-specific but not stage-
specific DNase I hypersensitive sites (HSs) and a variety of less
prominent HSs located between the major HSs. The human
-globin locus has a similar LCR. Although it is clear from
studies in which the LCR is deleted from the murine locus that
normal levels of expression require the LCR (3, 4), the mech-
anism by which the LCR (or any other enhancer) acts to increase
expression is unknown (reviewed in ref. 5) despite considerable
information concerning proteins bound there. There are several
plausible models but few experiments differentiate between
them (reviewed in ref. 6; ref. 7). One model assumes that the
LCR forms a large protein–DNA complex that physically inter-
acts with the promoter of the gene it is activating, with the
intervening DNA looped out (looping) (8, 9). An alternative is
that activators bound to the LCR either proceed down the
chromatin fiber until they reach and bind to a promoter (track-
ing) or form a chain of proteins that reaches and activates the
promoter (linking). Another possible mechanism is that the LCR
does not interact with promoters either directly or indirectly but
rather directs the locus to a subnuclear compartment in which
high levels of transcription can be achieved.
When linked individually to the LCR in transgenic mice, the
stage specificity of the embryonic () and fetal (G and A)
human -like globin genes is similar to that from large transgenes
that contain the whole locus in its normal arrangement (10–13).
Thus, the developmental-specific expression of these genes
seems to be regulated by proximal elements. However, when the
 gene is linked directly to the LCR in transgenes, it is dereg-
ulated and expressed throughout development (14–17). Proper
regulation is largely restored when a  gene is interposed
between the  gene and the LCR (16, 17). These and other
experiments involving rearrangements of -globin genes in
transgenic human loci in mice (18–20) have suggested that
expression of one -globin gene interferes with expression of
other genes within the locus. Furthermore, these experiments
have suggested that the appropriate developmental pattern of
-globin gene expression depends on the arrangement of the
genes within the locus. In general, genes located more proximal
to the LCR are activated to higher levels and at earlier devel-
opmental stages than those located more distally; full activation
of the distal genes seems to require the autonomous silencing of
the proximal genes.
The apparent role of proximity to the LCR in -globin gene
switching has led to the prevalent hypothesis of an active
competition between -globin gene promoters for physical in-
Abbreviations: LCR, locus control region; HS, DNase hypersensitive site; D, diffuse -globin
haplotype; S, single -globin haplotype.
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teraction with the LCR, which presumably provides an activity
that is otherwise rate-limiting for transcription (reviewed in ref.
7). A more proximal -globin gene would be favored for
interaction with the LCR because of the higher probability, in a
random walk model, of an LCR-bound protein complex con-
tacting it. When the proximal gene is silenced, the LCR is free
to interact with the distal gene. The finding that a  gene driven
by the spectrin promoter did not suppress  in the embryo when
it was interposed between the LCR and  in a transgene suggests
that such potential competition may be promoter-specific (21).
The role of the LCR in -globin gene switching is develop-
mentally neutral. Deletion of the LCR at the murine locus (3, 4)
or its omission in human transgenes (22) results in a severe
decrease in expression levels of all the genes but does not affect
the developmental pattern of gene expression. Thus, all the
necessary information for developmental-specific -globin gene
expression is encoded within gene-proximal elements, and the
LCR seems to act by increasing transcription levels at all
developmental stages. Although the results of some studies of
deletions of individual LCR elements in transgenic human
-globin loci have led to the suggestion of stage-specific roles for
these elements (23), this conclusion is not true for the murine
locus (24–26) and is unclear for human locus transgenes in
general. Deletions of different HSs from human transgenes have
parallel effects on developmental regulation, with the greatest
decreases in expression occurring at the embryonic and fetal
stages (9, 27–29). These results suggest that any given HS
deletion is not associated with a defect in switching but that there
is a general difference in sensitivity of the human locus to LCR
mutations at different developmental stages.
To date, models of developmental regulation of -globin gene
expression have been derived mostly from studies of transgenic
human loci. It is not clear yet that all effects seen in studies of
transgenes apply to the endogenous human or mouse loci. To
further test models of -globin gene switching and LCR–gene
interactions, we have examined the effects of promoter deletions
in the mouse -globin locus. The looping model predicts that
when two genes are expressed at the same stage of development,
deletion of either gene promoter will increase expression of the
remaining gene, because a competitor for direct physical inter-
action is removed (reviewed in ref. 7). A trackinglinking model
predicts that the gene that is closer to the LCR would likely
interfere with transmission of the signal to the downstream gene,
and therefore deletion of the proximal gene might increase
expression of more distal genes, whereas deletion of a distal gene
promoter would not be expected to affect expression of more
proximal genes (6). If the LCR directs subnuclear localization of
the locus, deletion of one promoter would not affect expression
of the remaining genes. The models are not mutually exclusive,
and more complex models are also possible.
The murine -globin locus is a good system to test gene
interaction effects, because there are two genes expressed in yolk
sac-derived primitive cells and two genes expressed in definitive
cells from fetal liver or bone marrow. Gene interactions there-
fore can be examined between normally expressed genes at
either stage. We report here the effects of deletion of the
promoter of either the murine Ey or h1 genes.
Materials and Methods
Constructs. The targeting vector for Ey promoter deletion (pEy-
prd-Hygro) consists of a 2.6-kb XbaI fragment located between
Ey and HS1 as the 5 homologous arm, a loxP site-f lanked
selectable marker (phosphoglycerate kinase I gene promoter
driving the hygromycin resistance gene), and a 3.7-kb BamHI
fragment spanning Ey intron 2 and exon 3 as the 3 homologous
arm. The targeting vector for h1 promoter deletion (ph1prd-
Neo) contains a 3.4-kb BamHI–HincII fragment between Ey and
the h1promoter as the 5 homologous arm, a loxP-flanked
selectable marker (phosphoglycerate kinase I gene promoter
driving a neomycin resistance gene), and a 2.6-kb HindIII
fragment spanning the h1 intron 2 and exon 3 and part of the
intergenic region between h1 and -major as the 3 homolo-
gous arm. Homologous fragments were isolated from a 129Sv
genomic library (Stratagene) and cloned into parent vector
pGEM-3Z with negative selection marker DT-A. Homologous
recombination replaced the Ey promoter from 673 to 442
and the h1 promoter from 11,010 to 12,208 (relative to the
cap site of Ey gene as 1) with the selectable marker.
Generation of Embryonic Gene Promoter Substitution and Deletion
Mice. Twenty micrograms of targeting vector was linearized with
SgrAI and electroporated into R1 embryonic stem cells for each
targeting construct. Embryonic stem cell clones were selected
with hygromycin (150 gml) for Ey promoter targeting and
G418 medium (180 gml) for h1 promoter targeting. Hygro-
mycin- and G418-resistant clones were confirmed for correct
targeting events by Southern blot hybridization with probes
differentiating the WT and targeted allele. Targeting frequency
was 15% for Eyhygro and 10% for h1neo. Multiple targeted
embryonic stem cell clones were used to inject day-3.5 blasto-
cysts from C57BL6 mice to generate chimeric mice. Chimeras
were backcrossed with C57BL6 mice to identify germ line-
transmitting founders. Mice were maintained in a mixed C57BL/
6129BALB/c background. These promoter-replacement
transgenic founders were bred with cytomegalovirus-Cre trans-
genic mice (30) (The Jackson Laboratory) to remove the select-
able marker and obtain promoter deletion mouse lines. All the
mutations were constructed on the diffuse haplotype. For assays
the mutantdiffuse -globin haplotype (D) males were mated
with C57BL6 [single -globin haplotype (S)S] females to get
mutant DS and WT DS littermate offspring and for timed
matings to get day-10.5 and day-15.5 embryos.
Steady-State mRNA Quantitation. Total RNAs were isolated with
RNA-Bee (Tel-Test, Friendswood, TX) from day-10.5 yolk sac,
day-15.5 fetal liver, and adult peripheral blood using manufac-
Fig. 1. Strategies for the murine -globin embryonic gene promoter dele-
tions. (A) Schematic map of the D haplotype murine-globin locus. Ey andh1
are solid boxes, and -major and -minor are open boxes. (B) Enlarged map of
Ey and h1 genes with exons numbered. The underlined regions are the
deletions. (C) Promoter substitution allele after homologous recombination.
The Ey promoter region is replaced by the PGK-Hygro gene flanked by loxP
sites. The h1 promoter region is replaced by the PGK-Neo gene flanked by
loxP sites. loxP sites are denoted by arrowheads. The horizontal arrows above
the selectable marker denote the transcription direction of the selectable
marker. (D) Promoter deletion alleles after selectable markers are removed by
Cre recombinase. The Cre-mediated reaction deletes the selectable marker
and leaves a 34-bp loxP site at the locus.
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turer instructions and were used for reverse transcription with
hexamer random primers. The method has been described in
detail (24). The primers used recognize Ey, h1, or -major and
-minor from both the D and S haplotypes of the murine
-globin locus. Amplified cDNA from each allele can be differ-
entiated by restriction-site polymorphisms between the diffuse
and single alleles in the amplified regions. Therefore the WT
single allele is the control for expression from the diffuse allele
with or without a mutation, and expression is presented as the
DS ratio of the mutant divided by the DS ratio of WT controls.
Quantitation is achieved by amplifying in the presence of
32P-labeled cytosine, running the reaction on a polyacrylamide
gel, and measuring the radioactivity in each band with a Phos-
phorImager (Molecular Dynamics). Assays used at least three
mice of each genotype for each analysis. Data are presented as
the mutant DS ratio divided by the WT DS ratio. Error bars
are the standard deviation between multiple individual mice of
a given genotype.
HPLC Assay of -Like Globin Gene Expression. To measure levels of
-major and -minor protein in bone marrow-derived erythro-
cytes, peripheral blood was collected from adult mice. The cells
were rinsed with mouse saline (170 mM NaCl) three times and
subjected to hemolysis and HPLC assay as described (31). Assays
used at least five mice of each genotype for each analysis, and the
data are presented similarly to the mRNA analysis.
Results
Production of Ey and h1 Gene Promoter Deletion Mice. To test the
hypothesis that expression of one embryonic globin gene inter-
feres with expression of the other globin genes through a
mechanism involving transcriptional interference, we used ho-
mologous recombination to replace the promoter region of
either Ey or h1 with a selectable marker. The promoter regions
and part of the coding region were deleted rather than the entire
gene to minimize structural perturbation of the locus, particu-
larly the distances from gene promoters to the LCR.
The strategy for these deletions involved using homologous
recombination in embryonic stem cells to replace the promoters
with selectable markers and then deletion of the selectable
markers by using Cre recombinase, as diagramed in Fig. 1, to
avoid any potential influence of the selectable marker on
regulation of the locus. Both targeting vectors were designed to
replace a 1.1-kb region from700 bp 5 to the transcription start
site to near the 3 end of exon 2. Drug-resistant clones were
analyzed, and targeted clones were identified by Southern blot
(Fig. 2). Additional Southern analyses with different restriction
digests and probes were used to confirm the integrity of the
homologous-recombination ends (data not shown). Mice de-
rived from the replacement with a selectable marker (denoted as
Eyhygro and h1neo) were bred with cytomegalovirus-Cre
transgenic mice (The Jackson Laboratory), which resulted in
deletion of the selectable marker in the F1 progeny with nearly
100% efficiency. These derived strains, denoted as Ey and
H1, were verified by Southern analyses as shown in Fig. 2.
Deletion of Either the Ey or h1 Promoter Has No Effect on Expression
of the Remaining Embryonic Gene. Loss of expression of a -like
globin gene will contribute to thalassemia and associated per-
turbation of erythropoiesis. To minimize such effects expression
is analyzed in heterozygous animals where expression from the
mutant allele is compared with expression from the WT allele of
a different haplotype in the same animal. The mutations de-
scribed here are on the D haplotype, whereas the control allele
is the WT S haplotype. The effects of mutation are reflected by
the ratio of gene expression between the mutant D allele and the
S allele, which are compared with the WT DS ratio (24). cDNA
from the D allele is distinguished from cDNA from the S allele
by a combined RT-PCRrestriction fragment length polymor-
phism assay. The system amplifies messages from either allele
with equal efficiency and uses restriction fragment length poly-
morphisms in the amplified region to differentiate the products
of each allele.
As expected, the Ey promoter deletion eliminates expression
of Ey (Fig. 2C). An assay of h1 mRNA from the embryonic yolk
sac shows no change in h1 expression compared with littermate
WT DS mice (Fig. 3).
Similar studies were performed on h1 mice. Using the
RT-PCR assay, we found that deletion of the h1 promoter also
completely eliminated h1 expression from the mutated allele
Fig. 2. Verification of deletion of Ey and h1 promoters and associated loss
of expression. (A) Southern blot strategy to differentiate WT diffuse, Eyhy-
gro, and Ey mice. The open box is the PGK-hygro-selectable marker. Sites for
the restriction enzyme ScaI are marked by S. (B) Ey Southern blot. Lane 1,
DD; lane 2, SS; lane 3, EyhygroS; lane 4, EyhygroEyhygro; lane 5,
EyD; lane 6,EyEy. (C) Representative RT-PCR assay of yolk-sac Ey expres-
sion in WT DS mice (WT) andEyS (Ey) mice. Expression from D and S alleles
is labeled. (D) Southern blot strategy to differentiate WT diffuse, h1neo,
and h1 mice. The open box is the PGK-neo-selectable marker. Sites for the
restriction enzyme NsiI are marked by N. (E) h1 Southern blot. Lane 1, DD;
lane 2, SS; lane 3, DS; lane 4,h1neoS; lane 5,h1D; lane 6,h1h1.
(F) Representative assay of yolk-sac h1 expression in WT DS mice (WT) and
h1S (h1) mice. Expression from D and S alleles is labeled.
Hu et al. PNAS  February 4, 2003  vol. 100  no. 3  1113
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(Fig. 2F). The deletion of the h1 promoter did not perturb
expression of Ey in the yolk sac (Fig. 3).
Deletion of Either the Ey or h1 Promoter Has No Effect on -Major
and -Minor Expression at Any Developmental Stage. To assay the
potential effect on expression of the adult -globin genes,
-major and -minor mRNA levels were quantified by an
RT-PCRrestriction fragment length polymorphism assay that is
similar to the assay used to quantify either Ey or h1 (24).
Although -major and -minor are expressed predominantly in
definitive cells, with a sufficiently sensitive assay their expression
can be detected in primitive cells. Based on the amount of
amplification required to get a clear signal, levels of -major and
-minor are 15- to 20-fold lower in yolk sac than in fetal liver.
As shown in Fig. 4, the expression of -major and -minor from
the D allele of either mutant or WT mice was similar to
expression of the cognate genes from the single allele in DS
heterozygous mice. This clearly shows that deletion of either one
of the promoters has not increased expression of -major and
-minor in the yolk sac.
Expression of -major and -minor was also assayed in
definitive erythrocyte precursor cells from fetal liver and reticu-
locytes from peripheral blood. As shown in Fig. 4, there was no
change in mRNA levels of -major and -minor in either the
Ey or h1 mice. This was confirmed by HPLC analysis of
globin proteins in mature erythrocytes from peripheral blood
(Fig. 4F).
Discussion
Implications for Models of LCR Mechanisms. Deletion of the Ey or
h1 gene promoters eliminated expression of the mutated gene
but had no effect on expression of the remaining genes in the
locus. This shows that there is no transcriptional interference
between the embryonic genes, and that embryonic -globin gene
expression is not limited by competition for LCR activity.
Although this observation does not prove or disprove any models
of LCR function fully, it does show that any LCR–promoter
interaction that does occur is not rate-limiting for murine
embryonic gene expression.
The expectation of competition has been implicit in the
looping model, which is based on the apparent intergenic
competition revealed by studies of human transgenes and
chicken globin genes (8). Most recently, analysis of nascent
mRNA transcripts by nuclear RNA-fluorescence in situ hybrid-
ization was used to suggest that active transcription alternates
between the Ey and h1 globin genes in primitive erythrocytes
(32), which if true would represent a strong indication of
Fig. 3. Deletion of either Ey gene promoter or h1 promoter does not
change mRNA expression of the remaining embryonic gene in the yolk sac. (A)
Representative assay of h1 expression in yolk sac of WT and Ey mice
heterozygous for the D and S alleles. (B) Representative assay of Ey expression
in yolk sac of WT andh1 mice heterozygous for the D and S alleles. (C) Graph
of composite data for mRNA expression of h1 in Ey mice and Ey in h1
mice. Shown is the mutant DS ratio divided by the WT DS ratio. WT values
are the WT DS ratio divided by itself to normalize all data to 1.0. Error bars
are the standard deviation of the mean for multiple individual mice before
normalization.
Fig. 4. Expression of -major (maj) and -minor (min) does not change at
any developmental stage in Ey or h1 mice. (A) Representative assay of
-major plus -minor expression in yolk sac from Ey mice. (B) Representative
assay of -major plus -minor expression in yolk sac from h1 mice. (C)
Representative assay of -major plus -minor expression in peripheral blood
fromEy mice. (D) Representative assay of -major plus -minor expression in
peripheral blood from h1 mice. (E) Graph of composite data for mRNA
expression of-major plus-minor in yolk sac, fetal liver, and peripheral blood
fromEy andh1 mice. Shown is the mutant DS ratio divided by the WT DS
ratio. WT values are the WT ratio divided by itself to normalize all data to 1.0.
Error bars are the standard deviation of the mean for multiple individual mice
before normalization. (F) Graph of composite data for protein assay by HPLC
from peripheral blood of Ey and h1 mice. Normalization and data pre-
sentation are done as described for B.
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competition between the two genes, perhaps for the activating
function of the LCR. However, based on the results reported
here, the looping model must be modified, at least in regard to
the murine embryonic -like globin genes. It is possible that for
these embryonic genes there is no physical interaction with the
LCR, and the looping model does not describe how the murine
embryonic genes interact with the LCR. Conversely, such a
physical interaction could occur simultaneously with both em-
bryonic genes, and therefore there is no competition despite a
requirement for the interaction. Perhaps the physical interaction
does occur with one promoter at a time but is not rate-limiting,
but this possibility would still undermine basic aspects of the
model substantially. Finally, it is formally possible that the
physical interaction occurs and is rate-limiting but involves
regions of the genes other than the promoters or first exon and
intron, which were deleted.
These results do not support the expectation from the track-
inglinking models that removal of a proximal gene would
increase expression of distal genes, because h1 gene expression
did not increase after deletion of the Ey promoter. Again,
however, more complex permutations of such models can ac-
commodate the data; for example, the active Ey promoter simply
may not interrupt the procession of proteins tracking or linking
along the chromatin fiber and thus would not influence expres-
sion of the h1 gene. The subnuclear localization model of LCR
function, which does not contain an implicit expectation of
transcriptional interference, is fully compatible with this result.
The experiments reported here show that the embryonic
murine genes are not in competition with each other, which
raises the question of whether the data from human transgenes
that support competition have any relevance to the murine locus.
There are data from a spontaneous mouse mutant, thal-1,
showing that transcriptional interference does occur between
the murine fetaladult genes. A 50% increase in -minor
transcription is observed in the thal-1 mouse, which has a
spontaneous 3-kb deletion of the -major gene and its promoter
(33). Combined with the data presented here, the thal-1 result
implies that the regulation of the fetaladult genes is fundamen-
tally different from the regulation of the embryonic genes. Such
differences could be due to gene-proximal effects such as
differences between the embryonic and fetaladult gene pro-
moters. Alternatively, because the embryonic genes are ex-
pressed in primitive erythrocytes and the fetaladult genes are
expressed predominantly in definitive erythrocytes, the different
regulation of these genes could represent a fundamental differ-
ence between these cell types. Finally, the greater size of the
deletion in the thal-1 mouse could encompass elements in
addition to the promoter that might interact with the LCR.
The currently favored model for human -globin gene switch-
ing, as applied to the mouse genes, proposes that expression of
the embryonic genes is required for suppression of the fetal
adult genes in primitive cells. Once again this is thought to
involve competition for physical interaction with the LCR
(reviewed in ref. 1). Deletion of Ey or h1 had no effect on the
fetaladult genes in the embryo, fetus, or adult. This shows that
deletion of one of the two embryonic genes is not sufficient to
up-regulate the fetaladult genes in the embryo and implies that
the fetaladult genes are not in competition with the embryonic
genes. However, it is possible that the remaining embryonic gene
is sufficient to compete with and suppress the fetaladult genes
despite the fact that the expression of the remaining embryonic
gene did not increase. Until a mouse line is produced with both
embryonic genes deleted from the same allele, this question
regarding the murine locus will remain open.
We acknowledge the Dartmouth Transgenic Mouse Shared Resource for
production of the chimeric mice used to establish the mutant mouse
lines. This work was supported by National Institutes of Health Grants
DK52854 (to S.F.), DK56845 and HL55435 (to E.E.B.), and DK44746
and HL57620 (to M.T.G.).
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